Keylika

Keylika is a biopharmaceutical startup focused on developing innovative metal-based drugs to address significant unmet medical needs. Utilizing a proprietary platform synthesis technology, Keylika engineers novel compounds and delivers them through established methods to optimize clinical outcomes. Their lead product is a first-in-class small molecule iron drug, administered via a wearable skin patch, designed to treat Iron Deficiency Anemia (IDA). This innovative approach aims to provide superior safety, efficacy, and tolerability compared to existing treatments. Keylika's transdermal iron patch has the potential to be a breakthrough therapy, eliminating the gastrointestinal side effects commonly associated with oral iron supplements and the risks, costs, and side effects linked to IV iron infusions. If approved, Keylika's proprietary patch would be the world's first prescription iron patch, targeting a substantial market driven by the widespread prevalence of iron deficiency, affecting approximately 1.6 billion people globally and over 30 million in the US, representing a $17 billion US market.